top of page

Recreational Use Vs. Psychotherapy-Assisted Use of Psychedelics: A Comparative Analysis

Psychedelic substances, including lysergic acid diethylamide (LSD), psilocybin, and 3,4-methylenedioxymethamphetamine (MDMA), have a history of both recreational and therapeutic use. While their recreational use is often associated with leisure and socializing, the context and purpose of psychedelic use in psychotherapy-assisted settings significantly diverge. Understanding the differences between these two use cases is essential for professionals in the mental health field and the general public alike.

Setting and Supervision:

A crucial distinction between recreational and psychotherapy-assisted use of psychedelics lies in the setting, the intention, and the level of professional supervision involved.

Recreational use often occurs in uncontrolled environments, such as at home, at parties, or festivals, where the primary goal is to experience altered states of consciousness for enjoyment, curiosity, or personal exploration. Such use is typically unsupervised and can involve higher risks, given the absence of professional guidance and the potential for adverse reactions in unpredictable environments.

In contrast, psychedelic-assisted psychotherapy takes place in controlled, safe environments under the supervision of trained professionals. Therapists help guide the experience, provide support, and ensure that the individual feels safe and comfortable throughout the process. The intention here is therapeutic, aimed at achieving specific mental health outcomes, such as reducing symptoms of PTSD or depression.

Dosage and Purity:

The dose and purity of psychedelics also significantly differ between recreational and therapeutic use. In recreational settings, the dosage and purity of the substances are often uncertain due to the lack of regulation, potentially leading to unpredictable and possibly harmful effects. Users may unknowingly consume adulterated substances or take doses that produce intense or uncomfortable experiences.

In therapeutic settings, professionals administer known, carefully calibrated doses of pure substances, mitigating the risks associated with uncertain dosage and impurity. Such control over dosage allows for safer, more predictable experiences, contributing to the therapy's efficacy.

Preparation and Integration:

Psychotherapy-assisted use of psychedelics involves structured preparation and integration phases, which are typically absent in recreational use.

Before a therapeutic psychedelic session, individuals undergo preparation, which includes establishing a therapeutic alliance, setting therapeutic intentions, and preparing for potential experiences. After the session, the integration phase allows individuals to make sense of their experiences and apply insights into their lives, contributing significantly to the therapeutic process.

Recreational users may lack these preparation and integration phases, potentially missing opportunities for personal growth or encountering challenging experiences they are unprepared to handle.

Therapeutic Outcomes Vs. Recreational Experiences:

While recreational use can occasionally lead to profound insights and personal growth, its primary purpose is often pleasure, social bonding, or exploration of altered states of consciousness.

Psychotherapy-assisted use, however, intentionally leverages the unique effects of psychedelics to facilitate therapeutic outcomes. The altered state of consciousness induced by psychedelics, when used within a therapeutic framework, can lead to significant shifts in perspective, emotional breakthroughs, and the reprocessing of traumatic memories.

Potential Risks and Adverse Reactions:

Both recreational and therapeutic use of psychedelics can lead to adverse reactions, but the risks are generally higher in recreational settings due to lack of professional supervision, uncertain dosage, and unpredictable environments. These risks can include "bad trips," characterized by intense fear or paranoia, accidental injuries, or the exacerbation of pre-existing mental health conditions.

Psychotherapy-assisted use, with its controlled setting, known dosages, and professional supervision, generally minimizes these risks. However, it's important to note that psychedelic-assisted therapy is not appropriate for everyone and can potentially lead to adverse reactions. Certain individuals, such as those with a personal or family history of psychosis, are typically screened out of therapeutic programs due to increased risk.

Long-term Implications:

Recreational use of psychedelics, especially frequent or high-dose use, has potential long-term risks, including psychological dependence, persistent perceptual changes, or exacerbation of mental health conditions. Furthermore, the illegal status of these substances in many regions means that recreational users may also face legal consequences.

In contrast, the goal of psychedelic-assisted psychotherapy is to achieve enduring positive change in mental health. Preliminary evidence suggests that these therapies may lead to significant, long-lasting reductions in symptoms of disorders such as PTSD, depression, and anxiety. The long-term implications of therapeutic use are an active area of research, with current studies examining potential lasting changes in personality, cognition, and emotional well-being.

Ethical Considerations:

The ethical considerations for recreational and psychotherapy-assisted use of psychedelics also differ considerably. For recreational use, ethical considerations often involve harm reduction – providing education and resources to minimize potential risks associated with use.

Psychotherapy-assisted use, on the other hand, involves a different set of ethical considerations. Therapists must obtain informed consent, explaining potential risks and benefits to clients. They must also adhere to professional guidelines to ensure that they are providing safe, effective, and equitable treatment.

The distinctions between recreational and psychotherapy-assisted use of psychedelics are significant and encompass the context of use, intention, dosage, potential risks, and long-term implications. Understanding these differences is essential for mental health professionals, policy-makers, and the general public. While recreational use can often be riskier and less predictable, the structured and professionally supervised nature of psychedelic-assisted psychotherapy offers a potentially powerful tool for mental health treatment. However, more research is needed to optimize these therapeutic interventions and fully understand their risks and benefits.

Reach out for integration support, or to learn more.

Psychotherapy-Assisted use of Psychedelics

  1. Nutt, D., Carhart-Harris, R., & Erritzoe, D. (2020). Psychedelic Psychiatry's Brave New World. Cell, 181(1), 24-28.

  2. Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992.

  3. Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of Psychopharmacology, 29(3), 289-299.

  4. Greer, G. R., & Tolbert, R. (1998). A method of conducting therapeutic sessions with MDMA. Journal of Psychoactive Drugs, 30(4), 371-379.

  5. Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355.

  6. Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology, 42(11), 2105-2113.

  7. MAPS - Multidisciplinary Association for Psychedelic Studies (2021). Investigator’s Brochure, Edition 9.

9 views0 comments


bottom of page